The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Open accessAbstract
The glucose transporter GLUT1 at the blood-brain barrier (BBB) mediates glucose transport into the brain. Alzheimer's disease is characterized by early reductions in glucose transport associated with diminished GLUT1 expression at the BBB. Whether GLUT1 reduction influences disease pathogenesis remains, however, elusive. Here we show that GLUT1 deficiency in mice overexpressing amyloid β-peptide (Aβ) precursor protein leads to early cerebral microvascular degeneration, blood flow reductions and dysregulation and BBB breakdown, and to accelerated amyloid β-peptide (Aβ) pathology, reduced Aβ clearance, diminished neuronal activity, behavioral deficits, and progressive neuronal loss and neurodegeneration that develop after initial cerebrovascular degenerative changes. We also show that GLUT1 deficiency in endothelium, but not in astrocytes, initiates the vascular phenotype as shown by BBB breakdown. Thus, reduced BBB GLUT1 expression worsens Alzheimer's disease cerebrovascular degeneration, neuropathology and cognitive function, suggesting that GLUT1 may represent a therapeutic target for Alzheimer's disease vasculo-neuronal dysfunction and degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Slc2a1 + / -mice with haploid deficiency in glucose transporter GLUT1 in brain endothelial cells develop microvascular reductions with BBB breakdown including loss of TJ and basement membrane proteins (649), whereas knockout of murine Mfsd2a gene results in not only diminished brain uptake of docosahexaenoic acid (DHA) in the form of lysophosphatidylcholine, but also leads to dysregulated cave”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since glucose concentration is lower in the brain interstitial fluid (ISF) compared with plasma, GLUT1 favors blood-to-brain transport of circulating glucose (141, 390, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glut1 + / -mice phenocopy human pathology, and develop initially within 2-3 wk of age BBB breakdown with loss of tight junctions and diminished glucose uptake by the brain, which is followed by microvascular regression, reduced brain perfusion and development of secondary neurodegenerative changes, microcephaly, and loss of cortical and hippocampal neurons (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental studies also support diminished transport of 14 C-labeled glucose across the BBB in haploinsufficient Slc2a1 + / -mice lacking ~50% copies of the GLUT1 BBB transporter (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduced activity and expression of the GLUT-1 transporter in the BBB suggest decreased glucose uptake and utilization by the brain,360,363 which may further exacerbate cerebrovascular degeneration, BBB breakdown, and Aβ pathology in models overexpressing APP, inducing neurodegeneration and cognitive deficits (Fig. 4).364”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [364]
The cited source says what the claim attributes to it.
In the citing paper
“reduced GLUT1 levels may also inhibit LRP1 transcriptionally via sterol regulatory element binding protein 2 (SREBP2) (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“Brain endothelial specific or enriched transporters are often indispensable for BBB barriergenesis, as for example, the glucose transporter-1 (GLUT1) (649), sodium-dependent lysophosphatidylcholine (LPC) symporter, the major facilitator superfamily (MFS) domain-containing protein 2a (MFSD2A) (62), and monocarboxylic acid transporter MCT8 (611).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“Since glucose concentration is lower in the brain interstitial fluid (ISF) compared with plasma, GLUT1 favors blood-to-brain transport of circulating glucose (141, 390, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“GLUT1 is expressed in endothelial cells, but not in neurons (141, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“For example, LRP1 minigene delivery to the BBB by viral vectors facilitates A 𝛃 clearance and attenuates A 𝛃 pathology (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“which we know leads to severe neurological phenotype in the GLUT1-deficiency syndrome (630, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448
Self-citationRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293
Self-citationAssessing nest building in mice
Deacon, R. M. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.170 · Cited by 1,115
Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid
Nguyen, L. N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., Wenk, M. R., Goh, E. L. K., & Silver, D. L. (2014) · Nature · doi:10.1038/nature13241 · Cited by 1,048
Flagged first, then by citations
Cited by
Sorted by citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Self-citationBlood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Self-citationThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670
Self-citationSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
The role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767
Brain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
Self-citationAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
Self-citationVascular heterogeneity and specialization in development and disease
Potente, M., & Mäkinen, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.36 · Cited by 653
The dynamic blood–brain barrier
Keaney, J., & Campbell, M. (2015) · The FEBS Journal · doi:10.1111/febs.13412 · Cited by 616
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Self-citationFibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527
Development and Cell Biology of the Blood-Brain Barrier
Langen, U. H., Ayloo, S., & Gu, C. (2019) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062608 · Cited by 533
Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability
García‐Cáceres, C., Quarta, C., Varela, L., Gao, Y., Gruber, T., Legutko, B., Jastroch, M., Johansson, P., Ninkovic, J., Yi, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.028 · Cited by 533
Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain
Kisler, K., Nelson, A. R., Rege, S. V., Ramanathan, A., Wang, Y., Ahuja, A., Lazic, D., Tsai, P. S., Zhao, Z., Zhou, Y., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4489 · Cited by 497
Self-citationGejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451
Lochhead, J. J., Yang, J., Ronaldson, P. T., & Davis, T. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00914 · Cited by 445
Neuronal regulation of the blood–brain barrier and neurovascular coupling
Kaplan, L., Chow, B. W., & Gu, C. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-0322-2 · Cited by 455
Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426
Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss
Nikolakopoulou, A. M., Montagne, A., Kisler, K., Dai, Z., Wang, Y., Huuskonen, M. T., Sagare, A. P., Lazić, D., Sweeney, M. D., Kong, P., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0434-z · Cited by 386
Self-citationThe Molecular Constituents of the Blood–Brain Barrier
Chow, B. W., & Gu, C. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.003 · Cited by 391
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 376
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Astrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355
Montagne, A., Nikolakopoulou, A. M., Zhao, Z., Sagare, A. P., Si, G., Lazic, D., Barnes, S. R., Daianu, M., Ramanathan, A., Go, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4482 · Cited by 344
Self-citationRetractedRom, S., Zuluaga‐Ramirez, V., Gajghate, S., Seliga, A., Winfield, M., Heldt, N. A., Kolpakov, M. A., Bashkirova, Y. V., Sabri, A. K., & Persidsky, Y. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1195-5 · Cited by 343
Douce, J. L., Maugard, M., Veran, J., Matos, M., Jégo, P., Vigneron, P.-A., Faivre, É., Toussay, X., Vandenberghe, M. E., Balbastre, Y., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.004 · Cited by 336
Ketogenic Diet in Alzheimer’s Disease
Rusek, M., Pluta, R., Ułamek-Kozioł, M., & Czuczwar, S. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163892 · Cited by 319
Factors influencing the blood-brain barrier permeability
Zhao, Y., Gan, L., Ren, L., Lin, Y., Ma, C., & Lin, X. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147937 · Cited by 291
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 281
Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy
Peng, X., Luo, Z., He, S., Zhang, L., & Li, Y. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.768108 · Cited by 284
Role of the Blood-Brain Barrier in Central Nervous System Insulin Resistance
Rhea, E. M., & Banks, W. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00521 · Cited by 272
Bridging barriers: a comparative look at the blood–brain barrier across organismsPreprint
O’Brown, N. M., Pfau, S. J., & Gu, C. (2018) · Genes & Development · doi:10.1101/gad.309823.117 · Cited by 267
The Impact of Disease Comorbidities in Alzheimer’s Disease
Santiago, J. A., & Potashkin, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631770 · Cited by 259
Blood-brain barrier transport machineries and targeted therapy of brain diseases
Barar, J., Rafi, M. A., Pourseif, M. M., & Omidi, Y. (2016) · Bioimpacts · doi:10.15171/bi.2016.30 · Cited by 259
Myelin dynamics: protecting and shaping neuronal functions
Saab, A. S., & Nave, K. (2017) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.09.013 · Cited by 270
Andersen, J. V., Schousboe, A., & Verkhratsky, A. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102331 · Cited by 263
Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity
Jaïs, A., Solas, M., Backes, H., Chaurasia, B., Kleinridders, A., Theurich, S., Mauer, J., Steculorum, S. M., Hampel, B., Goldau, J., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.033 · Cited by 262
Hussain, B., Fang, C., & Chang, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.688090 · Cited by 255
Gpr124 is essential for blood–brain barrier integrity in central nervous system disease
Chang, J., Mancuso, M. R., Maier, C. M., Liang, X., Yuki, K., Yang, L., Kwong, J. W., Wang, J., Rao, V., Vallon, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4309 · Cited by 255
Tight junction modulation of the blood brain barrier: CNS delivery of small molecules
Greene, C., & Campbell, M. (2016) · Tissue Barriers · doi:10.1080/21688370.2015.1138017 · Cited by 253
Veys, K., Fan, Z., Ghobrial, M., Bouché, A., García‐Caballero, M., Vriens, K., Conchinha, N. V., Seuwen, A., Schlegel, F., Gorski, T., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316463 · Cited by 252
Self-citationDewanjee, S., Chakraborty, P., Bhattacharya, H., Chacko, L., Singh, B., Chaudhary, A., Javvaji, K., Pradhan, S. R., Vallamkondu, J., Dey, A., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.032 · Cited by 243
Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lü, A., & Yang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020381 · Cited by 228
Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease
Wang, Q., Huang, X., Su, Y., Yin, G., Wang, S., Yu, B., Li, H., Qi, J., Chen, H., Zeng, W., et al. (2022) · Brain · doi:10.1093/brain/awac236 · Cited by 226
Clearance of Amyloid Beta and Tau in Alzheimer’s Disease: from Mechanisms to Therapy
Xin, S.-H., Tan, L., Cao, X., Yu, J.-T., & Tan, L. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9895-1 · Cited by 222
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Li, Y., Zhang, J., Wan, J., Liu, A., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110887 · Cited by 214
Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
Szablewski, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160841 · Cited by 211
Castelli, V., Benedetti, E., Antonosante, A., Catanesi, M., Pitari, G., Ippoliti, R., Cimini, A., & d’Angelo, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00132 · Cited by 224
Tian, Z., Ji, X., & Liu, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116224 · Cited by 223
Ramanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
Self-citationGlucose metabolic crosstalk and regulation in brain function and diseases
Zhang, S., Lachance, B. B., Mattson, M. P., & Jia, X. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102089 · Cited by 213
Yamazaki, Y., Shinohara, M., Shinohara, M., Yamazaki, A., Murray, M. E., Liesinger, A. M., Heckman, M. G., Lesser, E. R., Parisi, J. E., Petersen, R. C., et al. (2019) · Brain · doi:10.1093/brain/awz011 · Cited by 202
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Cedernaes, J., Osorio, R. S., Varga, A. W., Kam, K., Schiöth, H. B., & Benedict, C. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.02.002 · Cited by 210
Chen, T., Dai, Y., Hu, C., Lin, Z., Wang, S., Yang, J., Zeng, L., Li, S., & Li, W. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00557-1 · Cited by 205
Human pluripotent stem cell–derived brain pericyte–like cells induce blood-brain barrier properties
Stebbins, M. J., Gastfriend, B. D., Canfield, S. G., Lee, M.-S., Richards, D., Faubion, M. G., Li, W.-J., Daneman, R., Palecek, S. P., & Shusta, E. V. (2019) · Science Advances · doi:10.1126/sciadv.aau7375 · Cited by 195
Montagne, A., Nikolakopoulou, A. M., Huuskonen, M. T., Sagare, A. P., Lawson, E. J., Lazic, D., Rege, S. V., Grond, A., Zuniga, E., Barnes, S. R., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00073-z · Cited by 188
Self-citationVascular contributions to Alzheimer's disease
Eisenmenger, L. B., Peret, A., Famakin, B. M., Spahic, A., Roberts, G. S., Bockholt, J. H., Johnson, K. M., & Paulsen, J. S. (2022) · Translational research · doi:10.1016/j.trsl.2022.12.003 · Cited by 183
Gut commensal derived-valeric acid protects against radiation injuries
Li, Y., Dong, J., Xiao, H., Zhang, S., Wang, B., Cui, M., & Fan, S. (2020) · Gut Microbes · doi:10.1080/19490976.2019.1709387 · Cited by 177
A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease
Kyrtata, N., Emsley, H. C. A., Sparasci, O., Parkes, L. M., & Dickie, B. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.626636 · Cited by 171
Timper, K., del Río-Martín, A., Cremer, A. L., Bremser, S., Alber, J., Giavalisco, P., Varela, L., Heilinger, C., Nolte, H., Trifunovic, A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.001 · Cited by 170
Sato, N., & Morishita, R. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00199 · Cited by 167
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163
Precision drug delivery to the central nervous system using engineered nanoparticles
Gao, J., Xia, Z. J., Gunasekar, S., Jiang, C., Karp, J. M., & Joshi, N. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00695-w · Cited by 163
Endothelial response to glucose: dysfunction, metabolism, and transport
Clyne, A. M. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200611 · Cited by 168
Blood–brain barrier link to human cognitive impairment and Alzheimer’s disease
Barisano, G., Montagne, A., Kisler, K., Schneider, J. A., Wardlaw, J. M., & Zlokovic, B. V. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00014-4 · Cited by 157
Microglia-Specific Metabolic Changes in Neurodegeneration
Aldana, B. I. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.03.006 · Cited by 158
Blood-Brain Barriers in Obesity
Rhea, E. M., Salameh, T. S., Logsdon, A. F., Hanson, A. J., Erickson, M. A., & Banks, W. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0079-3 · Cited by 166
Polymer-Based Drug Delivery Systems for Cancer Therapeutics
Ding, L., Agrawal, P. P., Singh, S. K., Chhonker, Y. S., Sun, J., & Murry, D. J. (2024) · Polymers · doi:10.3390/polym16060843 · Cited by 158
Blood brain barrier: A review of its anatomy and physiology in health and disease
Sharif, Y., Jumah, F., Coplan, L., Krosser, A., Sharif, Κ., & Tubbs, R. S. (2018) · Clinical Anatomy · doi:10.1002/ca.23083 · Cited by 151
Emerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes
Lendahl, U., Nilsson, P., & Betsholtz, C. (2019) · EMBO Reports · doi:10.15252/embr.201948070 · Cited by 148
Neuroketotherapeutics: A modern review of a century-old therapy
Koppel, S. J., & Swerdlow, R. H. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.05.019 · Cited by 142
Skike, C. E. V., Jahrling, J. B., Dorigatti, A. O., Sayre, N. L., Hussong, S. A., Ungvari, Z. I., Lechleiter, J. D., & Galván, V. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00570.2017 · Cited by 144
Current and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo-Mínguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 142
Restraint stress-induced morphological changes at the blood-brain barrier in adult rats
Sántha, P., Veszelka, S., Hoyk, Z., Mészáros, M., Walter, F. R., Tóth, A. E., Kiss, L., Kincses, A., Oláh, Z., Seprényi, G., et al. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00088 · Cited by 136
Brain Metabolic Alterations in Alzheimer’s Disease
Ardanaz, C. G., Ramírez, M. J., & Solas, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073785 · Cited by 135
Blood-brain barrier integrity in the pathogenesis of Alzheimer’s disease
Huang, Z., Wong, L., Su, Y., Huang, X., Wang, N., Chen, H., & Yi, C. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100857 · Cited by 135
High-speed volumetric two-photon fluorescence imaging of neurovascular dynamics
Fan, J. L., Rivera, J. A., Sun, W., Peterson, J., Haeberle, H., Rubin, S., & Ji, N. (2020) · Nature Communications · doi:10.1038/s41467-020-19851-1 · Cited by 131
Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A
Nikolakopoulou, A. M., Wang, Y., Ma, Q., Sagare, A. P., Montagne, A., Huuskonen, M. T., Rege, S. V., Kisler, K., Dai, Z., Körbelin, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202207 · Cited by 131
Self-citationKetogenic Diets for Adult Neurological Disorders
McDonald, T. J. W., & Cervenka, M. C. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0666-8 · Cited by 137
Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 133
Blood–Brain Barrier Dysfunction in the Pathogenesis of Major Depressive Disorder
Wu, S., Yin, Y., & Du, L. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01153-9 · Cited by 127
Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Unnikrishnan, M. K., Uddin, M. S., Mathew, G. E., Pratap, R., Marathakam, A., & Mathew, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.03.018 · Cited by 127
Fatty acids and their therapeutic potential in neurological disorders
Lei, E., Vacy, K., & Boon, W. C. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.02.014 · Cited by 128
Diversity of astroglial responses across human neurodegenerative disorders and brain aging
Ferrer, I. (2017) · Brain Pathology · doi:10.1111/bpa.12538 · Cited by 135
Kim, S., Jung, U. J., & Kim, S. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020386 · Cited by 129
Swarup, A., Samuels, I. S., Bell, B. A., Han, J. Y. S., Du, J., Massenzio, E., Abel, E. D., Boesze-Battaglia, K., Peachey, N. S., & Philp, N. J. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00410.2018 · Cited by 122
Self-citationMattishent, K., & Loke, Y. K. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12587 · Cited by 123
Contributions of Aging to Cerebral Small Vessel Disease
Silva, T. M. D., & Faraci, F. M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034338 · Cited by 121
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 131
Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H. M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X. Y., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 125
Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain
Zhang, S., Zhang, Y., Wen, Z., Yang, Y., Bu, T., Bu, X., & Ni, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1192602 · Cited by 130
Tang, M., Gao, G., Rueda, C. B., Yu, H., Thibodeaux, D. N., Awano, T., Engelstad, K., Sanchez‐Quintero, M. J., Yang, H., Li, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms14152 · Cited by 120
Metadata
- Authors
- Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., Sullivan, J. S., Zhao, Z., Meiselman, H. J., Wenby, R. B., Soto, J., Abel, E. D., Makshanoff, J., Zuniga, E., De Vivo, D. C., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Tokyo Medical and Dental University (JP)
- University of Rochester Medicine (US)
- University of Iowa (US)
- ORCID
- Venue
- Nature Neuroscience
- Published
- 2015-03-02
- Volume
- 18
- Issue
- 4
- Pages
- 521-530
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- PMC
- PMC4734893
- OpenAlex
- W1974266381
- Cited by
- 689
- References
- 63
- Citations by year
- 2026: 65 · 2025: 72 · 2024: 65 · 2023: 62 · 2022: 79 · 2021: 78 · 2020: 62 · 2019: 49 · 2018: 52 · 2017: 47 · 2016: 38 · 2015: 20
- FWCI
- 27.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Southern California
- National Institutes of Health
- National Institute on Aging (R01AG023084, R01AG039452, R37AG023084, AG039452, RF1AG039452, AG023084)
- National Heart, Lung, and Blood Institute (U01HL087947)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK092065)
- National Institute of Neurological Disorders and Stroke (NS034467, R37NS034467, R01NS034467)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- GLUT1, Alzheimer's disease, blood-brain barrier, brain endothelium, amyloid-beta, amyloid-beta clearance, glucose transport, neurodegeneration, cerebrovascular dysfunction, cognitive impairment, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Cerebrovascular Circulation, Disease Models, Animal, Endothelium, Vascular, Mice, Inbred C57BL, Mice, Transgenic, Amyloid beta-Peptides, Glucose Transporter Type 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
